{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T04:27:41Z","timestamp":1779164861382,"version":"3.51.4"},"reference-count":110,"publisher":"JLE","issue":"6","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["N\u00e9phrologie &amp; Th\u00e9rapeutique"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.nephro.2017.01.023","type":"journal-article","created":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T01:30:18Z","timestamp":1501551018000},"page":"439-447","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Microangiopathie thrombotique et cancer"],"prefix":"10.1684","volume":"13","author":[{"given":"Rania","family":"Kheder El-Fekih","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cl\u00e9ment","family":"Deltombe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hassan","family":"Izzedine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"18929","reference":[{"key":"10.1016\/j.nephro.2017.01.023_bib0555","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.ejim.2011.05.005","article-title":"Incidence of acute kidney injury in cancer patients: a Danish population-based cohort study","volume":"22","author":"Christiansen","year":"2011","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.nephro.2017.01.023_bib0560","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/ndt\/gfv320","article-title":"Onco-nephrology: a decalogue","volume":"31","author":"Cosmai","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2017.01.023_bib0565","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.semnephrol.2010.09.005","article-title":"Nephrotoxicity from chemotherapeutic agents: clinical manifestations, pathobiology, and prevention\/therapy","volume":"30","author":"Perazella","year":"2010","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.nephro.2017.01.023_bib0570","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/j.1365-2141.1962.tb06541.x","article-title":"Microangiopathic hemolytic anemia: the possible role of vascular lesions in pathogenesis","volume":"8","author":"Brain","year":"1962","journal-title":"Br J Haematol"},{"key":"10.1016\/j.nephro.2017.01.023_bib0575","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/00005792-197909000-00004","article-title":"Microangiopathic hemolytic anemia and cancer: a review","volume":"58","author":"Antman","year":"1979","journal-title":"Medicine"},{"key":"10.1016\/j.nephro.2017.01.023_bib0580","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1634\/theoncologist.12-1-11","article-title":"Disseminated malignancy misdiagnosed as thrombotic thrombocytopenic purpura: a report of 10\u00a0cases and a systematic review of the literature","volume":"12","author":"Francis","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.nephro.2017.01.023_bib0585","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1634\/theoncologist.2009-0067","article-title":"Cancer awareness in atypical thrombotic microangiopathies","volume":"14","author":"Oberic","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.nephro.2017.01.023_bib0590","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1600-0609.2010.01448.x","article-title":"Cancer-associated microangiopathic hemolytic anemia with thrombocytopenia: an important diagnostic consideration","volume":"85","author":"Elliott","year":"2010","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.nephro.2017.01.023_bib0595","first-page":"908","article-title":"Systemic malignancies as a cause of unexpected microangiopathic hemolytic anemia and thrombocytopenia","volume":"25","author":"George","year":"2011","journal-title":"Oncology"},{"key":"10.1016\/j.nephro.2017.01.023_bib0600","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1053\/j.ajkd.2015.02.340","article-title":"Thrombotic microangiopathy, cancer, and cancer drugs","volume":"66","author":"Izzedine","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2017.01.023_bib0605","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1182\/blood-2011-02-321315","article-title":"Small vessels, big trouble in the kidneys and beyond: hematopoietic stem cell transplantation-associated thrombotic microangiopathy","volume":"118","author":"Laskin","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.nephro.2017.01.023_bib0610","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1093\/ndt\/gfl507","article-title":"Gemcitabine-induced thrombotic microangiopathy: a systematic review","volume":"21","author":"Izzedine","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2017.01.023_bib0615","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1002\/cncr.20290","article-title":"Gemcitabine-associated thrombotic microangiopathy","volume":"100","author":"Humphreys","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.nephro.2017.01.023_bib0620","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.krcp.2015.06.001","article-title":"A case of gemcitabine-induced thrombotic microangiopathy in a urothelial tumor patient with a single kidney","volume":"34","author":"Ryu","year":"2015","journal-title":"Kidney Res Clin Pract"},{"key":"10.1016\/j.nephro.2017.01.023_bib0625","doi-asserted-by":"crossref","first-page":"5858","DOI":"10.1158\/1078-0432.CCR-11-0804","article-title":"Thrombotic microangiopathy with targeted cancer agents","volume":"17","author":"Blake-Haskins","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nephro.2017.01.023_bib0630","article-title":"Antineoplastic agents and thrombotic microangiopathy","author":"Garcia","year":"2016","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.nephro.2017.01.023_bib0635","series-title":"Devita Hellman and Rosenberg's cancer: principles and practice of oncology","first-page":"1822","article-title":"Metabolic emergencies","author":"Fojo","year":"2015"},{"key":"10.1016\/j.nephro.2017.01.023_bib0640","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.blre.2014.11.001","article-title":"A new paradigm: diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury","volume":"29","author":"Jodele","year":"2015","journal-title":"Blood Rev"},{"key":"10.1016\/j.nephro.2017.01.023_bib0645","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1681\/ASN.2004100843","article-title":"Renal failure associated with cancer and its treatment: an update","volume":"16","author":"Humphreys","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2017.01.023_bib0650","series-title":"Renal pathology","first-page":"1154","article-title":"Thrombotic microangiopathy","author":"Remuzzi","year":"1994"},{"key":"10.1016\/j.nephro.2017.01.023_bib0655","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1542\/pir.22-11-365","article-title":"Hemolytic-uremic syndrome","volume":"22","author":"Corrigan","year":"2001","journal-title":"Pediatr Rev"},{"key":"10.1016\/j.nephro.2017.01.023_bib0660","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/S0360-3016(02)03793-8","article-title":"Successful treatment of radiation nephropathy with angiotensin II blockade","volume":"55","author":"Cohen","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.nephro.2017.01.023_bib0665","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1002\/(SICI)1097-0142(19990501)85:9%3C2023::AID-CNCR21%3E3.0.CO;2-2","article-title":"A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy","volume":"85","author":"Fung","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.nephro.2017.01.023_bib0670","series-title":"Heptinstall's pathology of the kidney","first-page":"739","article-title":"Thrombotic microangiopathies","author":"Laszk","year":"2015"},{"key":"10.1016\/j.nephro.2017.01.023_bib0675","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","article-title":"VEGF inhibition and renal thrombotic microangiopathy","volume":"358","author":"Eremina","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2017.01.023_bib0680","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0272-6386(99)70194-0","article-title":"Thrombotic microangiopathy as a complication of long-term therapy with gemcitabine","volume":"33","author":"Flombaum","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2017.01.023_bib0685","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1186\/1756-0500-6-450","article-title":"Immunoglobulin A nephropathy with massive paramesangial deposits caused by anti-vascular endothelial growth factor therapy for metastatic rectal cancer: a case report and review of the literature","volume":"6","author":"Yahata","year":"2013","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.nephro.2017.01.023_bib0690","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/jjco\/hyv035","article-title":"Onco-nephrology: current concepts and future perspectives","volume":"45","author":"Kitai","year":"2015","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.nephro.2017.01.023_bib0695","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/ki.2012.484","article-title":"Glomerular diseases seen with cancer and chemotherapy: a narrative review","volume":"84","author":"Jhaveri","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2017.01.023_bib0700","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/PAP.0000000000000032","article-title":"Hematopoietic stem cell transplantation: graft versus host disease and pathology of gastrointestinal tract, liver and lung","volume":"21","author":"Kambham","year":"2014","journal-title":"Adv Anat Pathol"},{"key":"10.1016\/j.nephro.2017.01.023_bib0705","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/PAP.0000000000000034","article-title":"Renal pathology associated with hematopoietic stem cell transplantation","volume":"21","author":"Troxell","year":"2014","journal-title":"Adv Anat Pathol"},{"key":"10.1016\/j.nephro.2017.01.023_bib0710","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/bmt.2016.61","article-title":"Post-bone marrow transplant thrombotic microangiopathy","volume":"51","author":"Obut","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.nephro.2017.01.023_bib0715","first-page":"292","article-title":"Is thrombotic microangiopathy a paraneoplastic phenomenon? Case report and review of the literature","volume":"4","author":"Houston","year":"2011","journal-title":"NDT Plus"},{"key":"10.1016\/j.nephro.2017.01.023_bib0720","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/MD.0b013e3182603598","article-title":"Cancer-related microangiopathic hemolytic anemia clinical and laboratory features in 168\u00a0reported cases","volume":"91","author":"Lechner","year":"2012","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.nephro.2017.01.023_bib0725","first-page":"74","article-title":"Thrombotic microangiopathy with severe renal failure in adenocarcinoma","volume":"18","author":"Lakshminarayana","year":"2008","journal-title":"J Nephrol"},{"key":"10.1016\/j.nephro.2017.01.023_bib0730","doi-asserted-by":"crossref","first-page":"345","DOI":"10.2215\/CJN.02070508","article-title":"Renal thrombotic microangiopathy after hematopoietic cell transplant: role of GVHD in pathogenesis","volume":"4","author":"Changsirikulchai","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2017.01.023_bib0735","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/modpathol.2016.61","article-title":"Renal pathology in hematopoietic cell transplant recipients: a contemporary biopsy, nephrectomy, and autopsy series","volume":"29","author":"Brinkerhoff","year":"2016","journal-title":"Mod Pathol"},{"key":"10.1016\/j.nephro.2017.01.023_bib0740","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/nrneph.2015.81","article-title":"Kidney diseases associated with haematological cancers","volume":"11","author":"Ganguli","year":"2015","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.nephro.2017.01.023_bib0745","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1053\/j.ackd.2013.07.004","article-title":"Kidney involvement in leukemia and lymphoma","volume":"21","author":"Luciano","year":"2014","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.nephro.2017.01.023_bib0750","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1177\/1078155214531804","article-title":"Carfilzomib-related acute kidney injury may be prevented by N-acetyl-L-cysteine","volume":"21","author":"Wanchoo","year":"2015","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.nephro.2017.01.023_bib0755","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/1471-2369-15-156","article-title":"Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma","volume":"15","author":"Hobeika","year":"2014","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.nephro.2017.01.023_bib0760","doi-asserted-by":"crossref","first-page":"6719","DOI":"10.1200\/JCO.2005.11.437","article-title":"Phase I trial of recombinant immunotoxin RFB4 (dsFv)-PE38 (BL22) in patients with B-cell malignancies","volume":"23","author":"Kreitman","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nephro.2017.01.023_bib0765","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJM200107263450402","article-title":"Efficacy of the anti-CD22\u00a0recombinant immunotoxin BL22\u00a0in chemotherapy-resistant hairy-cell leukemia","volume":"345","author":"Kreitman","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2017.01.023_bib0770","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1200\/JCO.2008.20.2630","article-title":"Phase II trial of recombinant immunotoxin RFB4 (dsFv)-PE38 (BL22) in patients with hairy cell leukemia","volume":"27","author":"Kreitman","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nephro.2017.01.023_bib0775","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1158\/1078-0432.CCR-08-1456","article-title":"CAT-8015: a second-generation pseudomonas exotoxin A-based immunotherapy targeting CD22-expressing hematologic malignancies","volume":"15","author":"Alderson","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nephro.2017.01.023_bib0780","first-page":"1302","article-title":"A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(\u00fe) CD22(\u00fe) B cell lymphoma","volume":"6","author":"Messmann","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nephro.2017.01.023_bib0785","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.3109\/10428190903186486","article-title":"A phase I\/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia","volume":"50","author":"Lin","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.nephro.2017.01.023_bib0790","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1046\/j.1523-1755.1999.00387.x","article-title":"A laboratory model of toxin-induced hemolytic uremic syndrome","volume":"55","author":"Taylor","year":"1999","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2017.01.023_bib0795","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0002-9440(10)62256-0","article-title":"Administration of ricin induces a severe inflammatory response via nonredundant stimulation of ERK, JNK, and P38\u00a0MAPK and provides a mouse model of hemolytic uremic syndrome","volume":"166","author":"Korcheva","year":"2005","journal-title":"Am J Pathol"},{"key":"10.1016\/j.nephro.2017.01.023_bib0800","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.2215\/CJN.03140312","article-title":"Onco-nephrology: AKI in the cancer patient","volume":"7","author":"Lam","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2017.01.023_bib0805","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s00280-016-2976-z","article-title":"Platinum-based drugs: past, present and future","volume":"77","author":"Dilruba","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.nephro.2017.01.023_bib0810","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1634\/theoncologist.2011-0422","article-title":"Is renal thrombotic angiopathy an emerging problem in the treatment of ovarian cancer recurrences?","volume":"17","author":"Kwa","year":"2012","journal-title":"Oncologist"},{"key":"10.1016\/j.nephro.2017.01.023_bib0815","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/bjh.12686","article-title":"Use of eculizumab in refractory gemcitabine-induced thrombotic microangiopathy","volume":"164","author":"Starck","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.nephro.2017.01.023_bib0820","first-page":"E30","article-title":"Eculizumab therapy for gemcitabine induced hemolytic uremic syndrome: case series and concise review","volume":"5","author":"Al Ustwani","year":"2014","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.nephro.2017.01.023_bib0825","doi-asserted-by":"crossref","first-page":"295323","DOI":"10.1155\/2014\/295323","article-title":"Eculizumab therapy leads to rapid resolution of thrombocytopenia in atypical hemolytic uremic syndrome","volume":"2014","author":"Tsai","year":"2014","journal-title":"Adv Hematol"},{"key":"10.1016\/j.nephro.2017.01.023_bib0830","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.revmed.2015.12.027","article-title":"[Clinical efficacy of eculizumab as treatment of gemcitabine-induced thrombotic microangiopathy: a case report]","volume":"37","author":"Rogier","year":"2016","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.nephro.2017.01.023_bib0835","article-title":"Gemcitabine-associated thrombotic microangiopathy: response to complement inhibition and reinitiation of gemcitabine","author":"Turner","year":"2016","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.nephro.2017.01.023_bib0840","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1472-6904-6-5","article-title":"Hemolytic uremic syndrome following the infusion of oxaliplatin: case report","volume":"6","author":"Dahabreh","year":"2006","journal-title":"BMC Clin Pharmacol"},{"key":"10.1016\/j.nephro.2017.01.023_bib0845","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/ajh.20516","article-title":"Immune-mediated thrombocytopenia resulting from sensitivity to oxaliplatin","volume":"81","author":"Curtis","year":"2006","journal-title":"Am J Hematol"},{"key":"10.1016\/j.nephro.2017.01.023_bib0850","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2165\/00002018-200124070-00002","article-title":"Drug-induced thrombotic microangiopathy: incidence, prevention and management","volume":"24","author":"Pisoni","year":"2001","journal-title":"Drug Saf"},{"key":"10.1016\/j.nephro.2017.01.023_bib0855","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1526-0968.2003.00127.x","article-title":"Drug-induced thrombotic thrombocytopenic purpura\/hemolytic uremic syndrome: a concise review","volume":"8","author":"Dlott","year":"2004","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.nephro.2017.01.023_bib0860","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1200\/JCO.1989.7.6.781","article-title":"Cancer-associated hemolytic-uremic syndrome: analysis of 85\u00a0cases from a national registry","volume":"7","author":"Lesesne","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nephro.2017.01.023_bib0865","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/1097-0142(19850101)55:1<47::AID-CNCR2820550108>3.0.CO;2-#","article-title":"Renal complications of mitomycin C therapy with special reference to the total dose","volume":"55","author":"Valavaara","year":"1985","journal-title":"Cancer"},{"key":"10.1016\/j.nephro.2017.01.023_bib0870","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.2215\/CJN.00860115","article-title":"Drug-induced glomerular disease: direct cellular injury","volume":"10","author":"Markowitz","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2017.01.023_bib0875","doi-asserted-by":"crossref","first-page":"130","DOI":"10.5414\/CNP71130","article-title":"Gemcitabine nephrotoxicity and hemolytic uremic syndrome: report of 29\u00a0cases from a single institution","volume":"71","author":"Glezerman","year":"2009","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.nephro.2017.01.023_bib0880","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s00277-007-0429-9","article-title":"Development of thrombotic thrombocytopenic purpura after a single dose of gemcitabine","volume":"87","author":"De Smet","year":"2008","journal-title":"Ann Hematol"},{"key":"10.1016\/j.nephro.2017.01.023_bib0885","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1002\/1097-0142(19861001)58:7<1428::AID-CNCR2820580709>3.0.CO;2-J","article-title":"A syndrome of microangiopathic hemolytic anemia, renal impairment, and pulmonary edema in chemotherapy treated patients with adenocarcinoma","volume":"58","author":"Sheldon","year":"1986","journal-title":"Cancer"},{"key":"10.1016\/j.nephro.2017.01.023_bib0890","doi-asserted-by":"crossref","first-page":"E16","DOI":"10.1053\/ajkd.2002.35758","article-title":"Gemcitabine-associated hemolytic-uremic syndrome","volume":"40","author":"Walter","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2017.01.023_bib0895","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1053\/ajkd.1998.v32.pm9708619","article-title":"Successful treatment of cisplatin-induced hemolytic uremic syndrome with therapeutic plasma exchange","volume":"32","author":"Palmisano","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2017.01.023_bib0900","doi-asserted-by":"crossref","first-page":"80","DOI":"10.5306\/wjco.v2.i2.80","article-title":"Tyrosine kinase inhibitors: multi-targeted or single-targeted?","volume":"2","author":"Broekman","year":"2011","journal-title":"World J Clin Oncol"},{"key":"10.1016\/j.nephro.2017.01.023_bib0905","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1038\/ki.2011.288","article-title":"Proteinuria and hypertension with tyrosine kinase inhibitors","volume":"80","author":"Kandula","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2017.01.023_bib0910","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s11523-015-0368-7","article-title":"Renal toxicities of targeted therapies","volume":"10","author":"Abbas","year":"2015","journal-title":"Target Oncol"},{"key":"10.1016\/j.nephro.2017.01.023_bib0915","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1053\/j.ajkd.2007.04.025","article-title":"Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension","volume":"50","author":"Izzedine","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2017.01.023_bib0920","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ejca.2009.11.001","article-title":"VEGF signaling inhibition-induced proteinuria: mechanisms significance management","volume":"46","author":"Izzedine","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.nephro.2017.01.023_bib0925","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1470-2045(07)70037-2","article-title":"Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma","volume":"8","author":"Frangie","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.nephro.2017.01.023_bib0930","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1093\/ndt\/gfn657","article-title":"Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib","volume":"24","author":"Bollee","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2017.01.023_bib0935","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1093\/ndt\/gfl565","article-title":"Thrombotic microangiopathy and anti-VEGF agents","volume":"22","author":"Izzedine","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2017.01.023_bib0940","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/ndt\/gft465","article-title":"All anti-vascular endothelial growth factor drugs can induce \u2018pre-eclampsialike syndrome\u2019: a RARe study","volume":"29","author":"Vigneau","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2017.01.023_bib0945","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/MD.0000000000000207","article-title":"Kidney diseases associated with anti-vascular endothelial growth factor (VEGF): an 8-year observational study at a single center","volume":"93","author":"Izzedine","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.nephro.2017.01.023_bib0950","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.amjmed.2008.11.025","article-title":"Renal effects of anti-angiogenesis therapy: update for the internist","volume":"122","author":"Gurevich","year":"2009","journal-title":"Am J Med"},{"key":"10.1016\/j.nephro.2017.01.023_bib0955","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1053\/j.ajkd.2004.12.017","article-title":"Thrombotic thrombocytopenic purpura in a patient treated with imatinib mesylate: true association or mere coincidence?","volume":"45","author":"Al Aly","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2017.01.023_bib0960","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1093\/ckj\/sfv059","article-title":"Thrombotic microangiopathy associated with proteasome inhibitors","volume":"8","author":"Lodhi","year":"2015","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.nephro.2017.01.023_bib0965","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1093\/ndt\/gfv222","article-title":"Bortezomib-induced acute interstitial nephritis","volume":"30","author":"Cheungpasitporn","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2017.01.023_bib0970","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1182\/blood-2014-01-492256","article-title":"Immunotoxins for leukemia","volume":"123","author":"Wayne","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.nephro.2017.01.023_bib0975","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.14694\/EdBook_AM.2015.35.e117","article-title":"What can we learn about antibody-drug conjugates from the T-DM1\u00a0experience?","author":"Esteva","year":"2015","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.nephro.2017.01.023_bib0980","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/ki.1994.417","article-title":"Acute renal failure in the setting of bone marrow transplantation","volume":"46","author":"Zager","year":"1994","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2017.01.023_bib0985","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1093\/ndt\/11.7.1332","article-title":"Haemolytic uraemic syndrome following bone marrow transplantation. Case report and review of the literature","volume":"11","author":"Verburgh","year":"1996","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2017.01.023_bib0990","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/sj.bmt.1705160","article-title":"Transplant-associated microangiopathy (TAM) in recipients of allogeneic hematopoietic stem cell transplants","volume":"36","author":"Martinez","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.nephro.2017.01.023_bib0995","first-page":"578A","article-title":"Sirolimus and thrombotic microangiopathy after allogeneic stem cell transplantation","volume":"15","author":"Henry","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2017.01.023_bib1000","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.bbmt.2005.04.007","article-title":"Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation","volume":"11","author":"Cutler","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.nephro.2017.01.023_bib1005","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2147\/JBM.S102235","article-title":"Hematopoietic cell transplantation-associated thrombotic microangiopathy: a review of pathophysiology, diagnosis, and treatment","volume":"7","author":"Rosenthal","year":"2016","journal-title":"J Blood Med"},{"key":"10.1016\/j.nephro.2017.01.023_bib1010","doi-asserted-by":"crossref","first-page":"368","DOI":"10.7326\/0003-4819-79-3-368","article-title":"Microangiopathic hemolytic anemia in metastatic carcinoma: report of eight cases","volume":"79","author":"Lohrmann","year":"1973","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.nephro.2017.01.023_bib1015","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1053\/ajkd.2002.36929","article-title":"Hemolytic uremic syndrome in metastatic adenocarcinoma of the prostate","volume":"40","author":"Mungall","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2017.01.023_bib1020","first-page":"1822","article-title":"Microangiopathic hemolytic anemia in metastasizing appendiceal carcinoma","volume":"30","author":"Neidhardt","year":"1979","journal-title":"Med Welt"},{"key":"10.1016\/j.nephro.2017.01.023_bib1025","first-page":"161","article-title":"Fatal Thrombotic Thrombocytopenic Purpura (TTP) presenting concurrently with metastatic Multiple Endocrine Neoplasia (MEN) type I","volume":"10","author":"Kouides","year":"1996","journal-title":"Hematopathol Mol Hematol"},{"key":"10.1016\/j.nephro.2017.01.023_bib1030","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/ajh.10366","article-title":"Thrombotic thrombocytopenic purpura associated with a prolactin-producing pituitary adenoma","volume":"74","author":"Kovacs","year":"2003","journal-title":"Am J Hematol"},{"key":"10.1016\/j.nephro.2017.01.023_bib1035","first-page":"171","article-title":"Malignant pheochromocytoma accompanied by microangiopathic hemolytic anemia: a case report","volume":"24","author":"Sakai","year":"1994","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.nephro.2017.01.023_bib1040","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1136\/jcp.2010.077511","article-title":"Phaeochromocytoma and thrombotic microangiopathy: favourable outcome despite advanced renal failure","volume":"63","author":"Schweizer","year":"2010","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.nephro.2017.01.023_bib1045","first-page":"172","article-title":"Disseminated intravascular coagulation due to malignancy","volume":"17","author":"Colman","year":"1990","journal-title":"Semin Oncol"},{"key":"10.1016\/j.nephro.2017.01.023_bib1050","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s12032-007-0048-2","article-title":"Breast cancer with an unusual leukemia-like presentation: case report and literature review","volume":"25","author":"Chang","year":"2008","journal-title":"Med Oncol"},{"key":"10.1016\/j.nephro.2017.01.023_bib1055","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S1470-2045(06)70730-6","article-title":"An acute-leukemia-like picture due to breast carcinoma cells","volume":"7","author":"Pitini","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.nephro.2017.01.023_bib1060","doi-asserted-by":"crossref","first-page":"4060","DOI":"10.1182\/blood-2010-07-271445","article-title":"How I treat patients with thrombotic thrombocytopenic purpura-2010","volume":"116","author":"George","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.nephro.2017.01.023_bib1065","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1182\/blood.V84.6.1765.1765","article-title":"Chimeric fusion protein toxin DAB486IL-2\u00a0in advanced mycosis fungoides and the Sezary syndrome: correlation of activity and interleukin-2\u00a0receptor expression in a phase II study","volume":"84","author":"Foss","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.nephro.2017.01.023_bib1070","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/j.1399-0012.2005.00334.x","article-title":"Anti-CD20\u00a0monoclonal antibody (Rituximab) for life-threatening hemolytic-uremic syndrome","volume":"19","author":"Yassa","year":"2005","journal-title":"Clin Transpl"},{"key":"10.1016\/j.nephro.2017.01.023_bib1075","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/sj.bmt.1705657","article-title":"Life-threatening hemolytic-uremic syndrome treated with rituximab in an allogeneic bone marrow transplant recipient","volume":"39","author":"Ostronov","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.nephro.2017.01.023_bib1080","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1111\/j.1537-2995.2007.01266.x","article-title":"Protein A immunoadsorption therapy for refractory, mitomycin C-associated thrombotic microangiopathy","volume":"47","author":"Kasper","year":"2007","journal-title":"Transfusion"},{"key":"10.1016\/j.nephro.2017.01.023_bib1085","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00280-008-0900-x","article-title":"Rituximab-based therapy for gemcitabine-induced hemolytic uremic syndrome in a patient with metastatic pancreatic adenocarcinoma: a case report","volume":"64","author":"Bharthuar","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.nephro.2017.01.023_bib1090","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jvir.2008.10.025","article-title":"Successful treatment of mitomycin-induced thrombotic thrombocytopenic purpura with rituximab","volume":"20","author":"Onitilo","year":"2009","journal-title":"Vasc Interv Radiol"},{"key":"10.1016\/j.nephro.2017.01.023_bib1095","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/0360-3016(92)90035-G","article-title":"Influence of renal shielding on the incidence of late renal dysfunction associated with T-lymphocyte deplete bone marrow transplantation in adult patients","volume":"23","author":"Lawton","year":"1992","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.nephro.2017.01.023_bib0550","doi-asserted-by":"crossref","first-page":"6152","DOI":"10.1200\/JCO.2009.22.2273","article-title":"Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors","volume":"27","author":"Langenberg","year":"2009","journal-title":"J Clin Oncol"}],"container-title":["N\u00e9phrologie &amp; Th\u00e9rapeutique"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725517301682?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725517301682?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.jle.com\/10.1016\/j.nephro.2017.01.023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T16:41:12Z","timestamp":1741192872000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1769725517301682"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":110,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S1769725517301682"],"URL":"https:\/\/doi.org\/10.1016\/j.nephro.2017.01.023","relation":{},"ISSN":["1769-7255"],"issn-type":[{"value":"1769-7255","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Microangiopathie thrombotique et cancer","name":"articletitle","label":"Article Title"},{"value":"N\u00e9phrologie & Th\u00e9rapeutique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nephro.2017.01.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Soci\u00e9t\u00e9 francophone de n\u00e9phrologie, dialyse et transplantation. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}